SCHEMBL4359199

SCHEMBL4359199

O=C1N=C(N2CCSCC2)SC1=Cc1cccc(C(=O)N2CCN(c3ncccc3Cl)CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 5/20 0.45
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 2/20 0.44
HTT P42858 2/20 0.44
MAPT P10636 1/20 0.44
HDAC1 Q13547 1/20 0.41
MEN1 O00255 1/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.41
TRPA1 O75762 1/20 0.41
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
AMY1A P0DUB6 1/20 0.40
DCTPP1 Q9H773 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4360746 1.00 ENPP2 (0.45) ENPP2ALDH1A1KMT2AHTTMAPT
SCHEMBL4354746 0.91 ENPP2 (0.46) ENPP2ALDH1A1KMT2AHTTMAPT
SCHEMBL4348140 0.91 ENPP2 (0.46) ENPP2ALDH1A1KMT2AHTTMAPT
SCHEMBL4356185 0.90 ENPP2 (0.43) ENPP2ALDH1A1KMT2AHTTMAPT
SCHEMBL4356182 0.90 ENPP2 (0.43) ENPP2ALDH1A1KMT2AHTTMAPT
SCHEMBL4364839 0.88 ENPP2 (0.41) ENPP2ALDH1A1KMT2AHTTMAPT
SCHEMBL4364835 0.88 ENPP2 (0.41) ENPP2ALDH1A1KMT2AHTTMAPT
SCHEMBL4348529 0.86 POLB (0.49) ENPP2ALDH1A1KMT2AHTTMAPT
SCHEMBL4348532 0.86 POLB (0.49) ENPP2ALDH1A1KMT2AHTTMAPT
SCHEMBL4352354 0.86 ALDH1A1 (0.45) ENPP2ALDH1A1KMT2AHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 ENPP2 1946/4885ALDH1A1 284/4885KMT2A 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.